1. Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT -methylated glioblastoma.
- Author
-
Liao X, Zhang S, Li X, Qian W, Li M, Chen S, Wu X, Yu X, Li Z, Tang M, Xu Y, Yu R, Zhang Q, Wu G, Zhang N, Song L, and Li J
- Subjects
- Humans, Animals, DNA Repair Enzymes metabolism, DNA Repair Enzymes genetics, Promoter Regions, Genetic genetics, DNA Methylation genetics, DNA Methylation drug effects, Checkpoint Kinase 1 metabolism, Checkpoint Kinase 1 genetics, Cell Line, Tumor, Mice, Brain Neoplasms genetics, Brain Neoplasms drug therapy, Brain Neoplasms pathology, Brain Neoplasms metabolism, Gene Expression Regulation, Neoplastic drug effects, RNA, Messenger metabolism, RNA, Messenger genetics, Phosphorylation drug effects, Glioblastoma genetics, Glioblastoma drug therapy, Glioblastoma pathology, Glioblastoma metabolism, Temozolomide pharmacology, Temozolomide therapeutic use, Drug Resistance, Neoplasm genetics, Drug Resistance, Neoplasm drug effects, RNA, Long Noncoding genetics, RNA, Long Noncoding metabolism, Tumor Suppressor Proteins metabolism, Tumor Suppressor Proteins genetics, DEAD-box RNA Helicases metabolism, DEAD-box RNA Helicases genetics, DNA Modification Methylases metabolism, DNA Modification Methylases genetics
- Abstract
The mechanisms underlying stimuli-induced dynamic structural remodeling of RNAs for the maintenance of cellular physiological function and survival remain unclear. Here, we showed that in MGMT promoter-methylated glioblastoma (GBM), the RNA helicase DEAD-box helicase 46 (DDX46) is phosphorylated by temozolomide (TMZ)-activated checkpoint kinase 1 (CHK1), resulting in a dense-to-loose conformational change and an increase in DDX46 helicase activity. DDX46-mediated tertiary structural remodeling of LINC01956 exposes the binding motifs of LINC01956 to the 3' untranslated region of O
6 -methylguanine DNA methyltransferase ( MGMT ). This accelerates recruitment of MGMT mRNA to the RNA export machinery and transportation of MGMT mRNA from the nucleus to the cytoplasm, leading to increased MGMT abundance and TMZ resistance. Using patient-derived xenograft (PDX) and tumor organoid models, we found that treatment with the CHK1 inhibitor SRA737abolishes TMZ-induced structural remodeling of LINC01956 and subsequent MGMT up-regulation, resensitizing TMZ-resistant MGMT promoter-methylated GBM to TMZ. In conclusion, these findings highlight a mechanism underlying temozolomide-induced RNA structural remodeling and may represent a potential therapeutic strategy for patients with TMZ-resistant MGMT promoter-methylated GBM.- Published
- 2024
- Full Text
- View/download PDF